Jianyuan Luo
Direttore/Membro del Consiglio presso Continent Pharmaceutical Inc.
Profilo
Jian Yuan Luo is an Independent Non-Executive Director at Continent Pharmaceutical Inc. and Beijing Continent Pharmaceutical Co., Ltd.
He is also a Council Member-Beijing Orphan Disease Brach at The Chinese Medical Association.
Previously, he worked as an Associate Professor at the University of Maryland from 2010 to 2015.
He received his undergraduate and graduate degrees from Peking University and his doctorate from the University of Kentucky.
Posizioni attive di Jianyuan Luo
| Società | Posizione | Inizio |
|---|---|---|
Continent Pharmaceutical Inc.
 Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Direttore/Membro del Consiglio | 01/01/2019 |
| The Chinese Medical Association | Corporate Officer/Principal | 01/02/2013 |
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Jianyuan Luo
| Società | Posizione | Fine |
|---|---|---|
| University of Maryland | Corporate Officer/Principal | 01/01/2015 |
Formazione di Jianyuan Luo
| Peking University | Undergraduate Degree |
| University of Kentucky | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
| The Chinese Medical Association | |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
- Borsa valori
- Insiders
- Jianyuan Luo